Published in N Engl J Med on July 07, 2011
Efficacy and Safety of Dapagliflozin in Acute Heart Failure (DICTATE-AHF) | NCT04298229
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA (2013) 4.84
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Retracted rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: a meta-analysis. Br J Clin Pharmacol (2015) 2.82
The role of the emergency department in acute heart failure clinical trials--enriching patient identification and enrollment. Am Heart J (2013) 1.95
De novo acute heart failure and acutely decompensated chronic heart failure. Dtsch Arztebl Int (2015) 1.93
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation (2016) 1.87
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol (2012) 1.66
A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J (2013) 1.65
Corin overexpression improves cardiac function, heart failure, and survival in mice with dilated cardiomyopathy. Hypertension (2012) 1.60
Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J (2013) 1.55
Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J (2013) 1.50
Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation (2013) 1.48
The lost decade of nesiritide. N Engl J Med (2011) 1.45
Potential effects of digoxin on long-term renal and clinical outcomes in chronic heart failure. J Card Fail (2013) 1.41
Identification of small molecule NPR-B antagonists by high throughput screening--potential use in heart failure. Naunyn Schmiedebergs Arch Pharmacol (2013) 1.39
Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides. JACC Heart Fail (2015) 1.38
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J (2012) 1.24
Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circ Heart Fail (2013) 1.21
Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. Am Heart J (2012) 1.17
The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol (2013) 1.03
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev (2014) 1.03
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail (2013) 1.02
In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization. J Am Heart Assoc (2014) 0.99
Protein kinase g iα inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc (2012) 0.99
Contemporary strategies in the diagnosis and management of heart failure. Mayo Clin Proc (2014) 0.98
Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol (2012) 0.95
Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. Eur J Heart Fail (2012) 0.95
Decongestion in acute heart failure. Eur J Heart Fail (2014) 0.94
Acute decompensated heart failure is routinely treated as a cardiopulmonary syndrome. PLoS One (2013) 0.92
Cardiorenal syndrome: new developments in the understanding and pharmacologic management. Clin J Am Soc Nephrol (2013) 0.91
Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin. Clin Res Cardiol (2015) 0.90
Molecular and cellular neurocardiology: development, and cellular and molecular adaptations to heart disease. J Physiol (2016) 0.89
GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail (2014) 0.88
Early changes in clinical characteristics after emergency department therapy for acute heart failure syndromes: identifying patients who do not respond to standard therapy. Heart Fail Rev (2012) 0.87
The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) (2016) 0.87
Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). Am Heart J (2015) 0.86
From hot hands to declining effects: the risks of small numbers. J Am Coll Cardiol (2012) 0.86
An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase G-mediated phosphodiesterase type 3 inhibition. Circulation (2011) 0.85
Physiology and clinical significance of natriuretic hormones. Indian J Endocrinol Metab (2013) 0.85
Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J (2014) 0.84
BNP molecular forms and processing by the cardiac serine protease corin. Adv Clin Chem (2013) 0.84
Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. Eur J Heart Fail (2012) 0.84
Relation of dyspnea severity on admission for acute heart failure with outcomes and costs. Am J Cardiol (2014) 0.84
Update on the Management of Acute Decompensated Heart Failure. Curr Treat Options Cardiovasc Med (2011) 0.84
New medical therapies for heart failure. Nat Rev Cardiol (2015) 0.83
Vasodilators in Acute Heart Failure: Review of the Latest Studies. Curr Emerg Hosp Med Rep (2014) 0.83
Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. Eur J Heart Fail (2015) 0.83
The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. Eur J Heart Fail (2015) 0.83
Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J (2015) 0.82
Arginine vasopressin as a target in the treatment of acute heart failure. World J Cardiol (2014) 0.82
Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. Acad Emerg Med (2014) 0.82
Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011. J Am Heart Assoc (2017) 0.82
Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev (2014) 0.81
Serelaxin in clinical development: past, present and future. Br J Pharmacol (2017) 0.81
Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. Circ Heart Fail (2014) 0.81
Acute heart failure: patient characteristics and pathophysiology. Curr Heart Fail Rep (2013) 0.80
Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vasc Health Risk Manag (2015) 0.80
Lack of evidence for intravenous vasodilators in ED patients with acute heart failure: a systematic review. Am J Emerg Med (2014) 0.80
What is the prognostic significance of pulmonary hypertension in heart failure? Circ Heart Fail (2011) 0.80
Novel renal biomarkers to assess cardiorenal syndrome. Curr Heart Fail Rep (2014) 0.80
Impaired sinoatrial node function and increased susceptibility to atrial fibrillation in mice lacking natriuretic peptide receptor C. J Physiol (2015) 0.80
Cardiac PDEs and crosstalk between cAMP and cGMP signalling pathways in the regulation of contractility. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.80
Natriuretic peptides in therapy for decompensated heart failure. Eur J Clin Pharmacol (2011) 0.80
Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy. Curr Heart Fail Rep (2013) 0.80
Current strategies for preventing renal dysfunction in patients with heart failure: a heart failure stage approach. Clinics (Sao Paulo) (2013) 0.79
Natriuretic Peptides and Cardiometabolic Health. Circ J (2015) 0.79
Pharmacologic Management of the Cardio-renal Syndrome. Electrolyte Blood Press (2013) 0.79
Mutation of the protein kinase I alpha leucine zipper domain produces hypertension and progressive left ventricular hypertrophy: a novel mouse model of age-dependent hypertensive heart disease. J Gerontol A Biol Sci Med Sci (2013) 0.79
Natriuretic peptide-induced catecholamine release from cardiac sympathetic neurons: inhibition by histamine H3 and H4 receptor activation. J Pharmacol Exp Ther (2012) 0.79
Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway. J Cardiovasc Transl Res (2013) 0.79
Assessment of dyspnea early in acute heart failure: patient characteristics and response differences between likert and visual analog scales. Acad Emerg Med (2014) 0.79
Airway Management & Assessment of Dyspnea in Emergency Department Patients with Acute Heart Failure. Curr Emerg Hosp Med Rep (2013) 0.78
Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. Braz J Med Biol Res (2014) 0.78
Renal dysfunction in acute heart failure. Korean Circ J (2011) 0.78
Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events. J Am Heart Assoc (2015) 0.78
Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. J Card Fail (2016) 0.78
Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. Ther Clin Risk Manag (2016) 0.78
Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects. Circ Heart Fail (2013) 0.78
Heart failure re-admission: measuring the ever shortening gap between repeat heart failure hospitalizations. PLoS One (2014) 0.78
Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.78
Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study. Adv Ther (2014) 0.78
Causes and treatment of oedema in patients with heart failure. Nat Rev Cardiol (2013) 0.78
Site selection for heart failure clinical trials in the USA. Heart Fail Rev (2015) 0.78
Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. Curr Heart Fail Rep (2017) 0.78
Effect of rhBNP on renal function in STEMI-HF patients with mild renal insufficiency undergoing primary PCI. Heart Vessels (2015) 0.78
Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol (2016) 0.77
Cardiorenal Syndrome Type 1: Renal Dysfunction in Acute Decompensated Heart Failure. J Clin Outcomes Manag (2015) 0.77
Use of carperitide infusion for acutely decompensated heart failure. Crit Care (2012) 0.77
The Prognostic Importance of Changes in Renal Function during Treatment for Acute Heart Failure Depends on Admission Renal Function. PLoS One (2015) 0.77
Acute decompensated heart failure update. Curr Cardiol Rev (2015) 0.77
Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. Eur J Heart Fail (2016) 0.77
Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide. J Card Fail (2014) 0.77
The dose-dependent effect of nesiritide on renal function in patients with acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials. PLoS One (2015) 0.77
A patient with heart failure and worsening kidney function. Clin J Am Soc Nephrol (2014) 0.77
Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome. Cardiorenal Med (2015) 0.77
Potential Expanded Indications for Neprilysin Inhibitors. Curr Heart Fail Rep (2017) 0.76
Pharmacological Therapy in the Heart as an Alternative to Cellular Therapy: A Place for the Brain Natriuretic Peptide? Stem Cells Int (2016) 0.76
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA (1996) 17.62
Evaluating the yield of medical tests. JAMA (1982) 14.05
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum (1991) 7.94
Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet (1988) 7.59
Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med (1993) 7.19
Regression modelling strategies for improved prognostic prediction. Stat Med (1984) 7.09
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med (1994) 6.78
Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med (1993) 6.45
Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. Endocrinology (1993) 6.20
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19
The vagus influences giving rise to the phenomena accompanying expansion and collapse of the lungs. J Physiol (1932) 5.96
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94
Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? N Engl J Med (1997) 5.80
Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J (2001) 5.77
Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ (2001) 5.63
Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med (1993) 5.59
Outcome of acute myocardial infarction according to the specialty of the admitting physician. N Engl J Med (1996) 5.51
A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol (1989) 5.50
Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA (1997) 5.47
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J (2005) 5.40
A systematic review of randomized trials of disease management programs in heart failure. Am J Med (2001) 5.38
Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis (2006) 5.20
The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med (1989) 5.10
Evaluation and management of traumatic lacerations. N Engl J Med (1997) 4.92
Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med (2001) 4.85
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet (1981) 4.75
Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med (2000) 4.73
Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol (2008) 4.57
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53
Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network. N Engl J Med (1999) 4.42
Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy. Neoplasia (2000) 4.42
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 4.36
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol (1999) 4.15
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation (1996) 4.01
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation (1996) 3.98
Sperm morphology, motility, and concentration in fertile and infertile men. N Engl J Med (2001) 3.97
Association between dental health and acute myocardial infarction. BMJ (1989) 3.94
Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant (2006) 3.78
Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J (2003) 3.78
Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet (2002) 3.77
Effects of admission to a teaching hospital on the cost and quality of care for Medicare beneficiaries. N Engl J Med (1999) 3.70
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med (1995) 3.69
Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med (1991) 3.63
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61
An epidemiological study of pulmonary arterial hypertension. Eur Respir J (2007) 3.60
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med (1995) 3.56
Quality-of-life changes and hearing impairment. A randomized trial. Ann Intern Med (1990) 3.52
Advancing paternal age and the risk of schizophrenia. Arch Gen Psychiatry (2001) 3.48
The cognitive neuroscience paradigm: a unifying metatheoretical framework for the science and practice of clinical psychology. J Clin Psychol (2001) 3.45
Referral patterns for coronary artery disease treatment: gender bias or good clinical judgment? Ann Intern Med (1992) 3.39
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38
Wasting as independent risk factor for mortality in chronic heart failure. Lancet (1997) 3.37
Scorecard cardiovascular medicine. Its impact and future directions. Ann Intern Med (1994) 3.32
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26
Some structural and biological properties of Brucella endotoxin. Infect Immun (1970) 3.26
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26
Surface antigens of smooth brucellae. J Bacteriol (1968) 3.24
Job strain and the prevalence and outcome of coronary artery disease. Circulation (1995) 3.22
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 3.20
Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: implications for secondary prevention efforts. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 3.17
Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med (1997) 3.13
Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Circulation (1998) 3.11
The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med (1995) 3.08
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. JAMA (1992) 3.06
Mannheim intima-media thickness consensus. Cerebrovasc Dis (2004) 3.05
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04
The endotoxin-lipoprotein hypothesis. Lancet (2000) 3.03
Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature (1998) 3.02
Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 3.01